Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
0
Authors
Wei Ding
Wei Ding•Betsy LaPlant•Stephen Ansell
Published
April 20, 2017
Abstract
Key Points Pembrolizumab was first shown to be clinically active in CLL patients with RT. PD-1 and PD-L1 expression in tumor microenvironment are promising biomarkers to select RT patients for PD-1 blockade.
